Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.

被引：0
|
作者：
Rittmeyer, Achim
Scherpereel, Arnaud
Gorbunova, Vera A.
Gervais, Radj
Vikstrom, Anders
Chouaid, Christos
Chella, Antonio
Kim, Joo-Hang
Ahn, Myung-Ju
Reck, Martin
Pazzola, Antonio
Kim, Heung Tae
Aerts, Joachim
Groen, Harry J. M.
Morando, Claire
Loundou, Anderson
Barlesi, Fabrice
机构：
[1] Lungenfachklin Immenhausen, Immenhausen, Germany
[2] CHU Lille, F-59037 Lille, France
[3] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia
[4] Ctr Francois Baclesse, F-14021 Caen, France
[5] Univ Sjukhuset, Linkoping, Sweden
[6] Hop St Antoine, F-75571 Paris, France
[7] Univ Hospita, Pisa, Italy
[8] Yonsei Canc Ctr, Yonsei Canc Res Inst, Dept Internal Med Med Oncol, Seoul, South Korea
[9] Sungkyunkwan Univ, Dept Med, Div Hematol Oncol, Samsung Med Ctr,Sch Med, Seoul, South Korea
[10] Lung Clin Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany
[11] Med Oncol Osped Civile SS Annunziata, Sassari, Italy
[12] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[13] Amphia Hosp, Breda, Netherlands
[14] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands
[15] Aix Marseille Univ, Marseille, France
[16] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8014
引用
收藏
页数：1
相关论文
共 50 条
  • [1] AVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or without pemetrexed (pem) in patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)-pem: Interim safety data.
    Barlesi, F.
    Scherpereel, A.
    Gervais, R.
    Gorbunova, V. A.
    Vikstroem, A.
    Ahn, M.
    Kim, J.
    Chella, A.
    Aerts, J.
    Ferrer, N.
    Perez, J. M. Trigo
    Lutiger, B.
    Rittmeyer, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev plus Pemetrexed (pem) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)
    Barlesi, F.
    de Castro, J.
    Dvornichenko, V.
    Kim, J. H.
    Pazzola, A.
    Rittmeyer, A.
    Vikstrom, A.
    Mitchell, L.
    Wong, E. K.
    Gorbunova, V.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : 16 - 16
  • [3] AVAPERL1 (MO22089) - Interim Safety of Maintenance (mtc) Bevacizumab (bev) plus Pemetrexed (pem) in Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)
    Ahn, M.
    Gervais, R.
    Mezger, J.
    Reck, M.
    Orlovs, S.
    Burgers, J. A.
    Bearz, A.
    Grossi, F.
    Lutiger, B.
    Barlesi, F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S626 - S626
  • [4] Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)
    Barlesi, Fabrice
    Scherpereel, Arnaud
    Rittmeyer, Achim
    Pazzola, Antonio
    Tur, Neus Ferrer
    Kim, Joo-Hang
    Ahn, Myung-Ju
    Aerts, Joachim G. J. V.
    Gorbunova, Vera
    Vikstrom, Anders
    Wong, Elaine K.
    Perez-Moreno, Pablo
    Mitchell, Lada
    Groen, Harry J. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (24) : 3004 - +
  • [5] Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
    Barlesi, F.
    Scherpereel, A.
    Gorbunova, V.
    Gervais, R.
    Vikstrom, A.
    Chouaid, C.
    Chella, A.
    Kim, J. H.
    Ahn, M. J.
    Reck, M.
    Pazzola, A.
    Kim, H. T.
    Aerts, J. G.
    Morando, C.
    Loundou, A.
    Groen, H. J. M.
    Rittmeyer, A.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (05) : 1044 - 1052
  • [6] Randomized phase III trial of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance Pem plus Bev (Pem arm) versus paclitaxel (Pac) plus Cb plus Bev followed by maintenance Bev (Pac arm) in patients (pts) with stage IIIb/IV nonsquamous non-small cell lung cancer (nsNSCLC) (POINTBREAK): African American (AA) subset.
    Reynolds, Craig H.
    Patel, Jyoti D.
    Garon, Edward B.
    Olsen, Mark R.
    Bonomi, Philip D.
    Govindan, Ramaswamy
    Obasaju, Coleman K.
    Pennella, Eduardo J.
    Liu, Jingyi
    Guba, Susan C.
    Spigel, David R.
    Hermann, Robert C.
    Socinski, Mark A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] MAINTENANCE BEVACIZUMAB (BV) WITH OR WITHOUT PEMETREXED (PEM) FOLLOWING FIRST-LINE BV-CISPLATIN (CIS)-PEM IN PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY SAFETY DATA FROM AVAPERL1 (MO22089)
    Barlesi, F.
    Pazzola, A.
    Gorbunova, V.
    Grossi, F.
    Kohler, M.
    Mezger, J.
    Peters, F. J.
    Trigo Perez, J. M.
    Vilkstrom, A.
    Groen, H. J. M.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 144 - 144
  • [8] First-line chemotherapy (CT) with pemetrexed (PEM) plus cisplatin (CIS) plus bevacuzimab (BEV) followed by maintenance PEM plus BEV for advanced nonsquamous non-small cell lung cancer (NS-NSCLC): Final results of a single-arm phase II study.
    Hillerdal, Gunnar N.
    Sorensen, Jens Benn
    Hoeffken, Gert
    Favaretto, Adolfo
    Perez-Carrion, Ramon
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Soldatenkova, Victoria
    Bourayou, Nawel
    Santoro, Armando
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] A phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance pem plus bev versus paclitaxel (Pac) plus cb plus bev followed by maintenance bev in stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC): Overall and age group results.
    Socinski, Mark A.
    Patel, Jyoti D.
    Garon, Edward B.
    Govindan, Ramaswamy
    Reynolds, Craig H.
    Spigel, David R.
    Olsen, Mark R.
    Liu, Jingyi
    Guba, Susan C.
    Bonomi, Philip
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Health-Related Quality of Life in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089)
    Rittmeyer, Achim
    Gorbunova, Vera
    Vikstrom, Anders
    Scherpereel, Arnaud
    Kim, Joo-Hang
    Ahn, Myung-Ju
    Chella, Antonio
    Chouaid, Christos
    Campbell, Alicyn K.
    Barlesi, Fabrice
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (11) : 1409 - 1416
12345